Join Megan Webster, PhD, Principal Scientist, for a talk on Lung Fibrosis at The 3Rs Collaborative (3RsC) webinar next week: 📌 'Utilisation of high-content imaging for the study of lung fibrosis.' Register here: buff.ly/3QSLDhr #Lung #Fibrosis #MPS

Colin Brown, Chief Scientific Officer, and Rhys Powell, Account Manager, are representing #Newcells at the 51st Annual Meeting of the Japanese Society of #Toxicology 🇯🇵 Come and say hi at booth #21! 👋 #JSOT #JSOT2024

🔬 AAV Vectors in Retinal #GeneTherapy: Insights from Human iPSC-Derived Retinal #Organoids 🧬Our recent study explores the tropism of AAV vectors in photoreceptor-like cells of human iPSC-derived retinal organoids. Read it here: newcellsbiotech.co.uk/resour… #Newcells

🔬Unlocking Insights into Fibrosis: The #FMT Assay This assay provides critical insights into #fibroticdiseases, outlining the importance of using culture conditions that promote fibroblast activation and matrix deposition for accurate #proteindetection: buff.ly/3Rxj4q1

📸 Recap of day three from the Newcells team at #MPSWorldSummit!📍 👂 Overheard by our booth: "Commercially available #retinalorganoids are a must for the industry. An absolute must." Chat to our wonderful team at booth #63 to find out why!

🌐 Join our upcoming webinar 🌐 Our experts will delve into strategies for streamlining the clinical development pipeline, with a special focus on retina-related compounds. 📅 June 19th ⏰ 2:00 PM BST Learn more and register: buff.ly/3XmDSEj #Newcells #Retina

Day one at #MPSWorldSummit!📍 Colin Brown, CSO, will present at 10am PDT on Thursday 13th: 📌 Developing predictive in vitro Glomerulus, Proximal Tubule and Loop of Henle renal cell model platforms to investigate the renal uptake and nephrotoxic liability of large molecules.

Can we speed up #drugdevelopment in #ophthalmology? Newcells’ iPSC-derived retinal organoids reconstitute the retinal architecture and provide more accurate in vitro to in vivo extrapolation (IVIVE). Learn more here 👉 buff.ly/3yrBUrI #Retina

🚀 Introducing aProximate Newcells’ advanced kidney platform revolutionising #drugdevelopment. ☑️ High-throughput #kidney proximal tubule cell model ☑️ Accurate prediction of in vivo outcomes ☑️ Transporter-mediated DDIs & nephrotoxicity data buff.ly/3V96VZb #Newcells

Current preclinical models of the retina have limitations. Newcells’ advanced retinal organoids and RPE models are 3D, functionally validated & fully characterised. Learn more about our models. Download our eBook here: buff.ly/3yrBUrI #Newcells #Retina #Organoids

Kidney nephron models: drug transporter interactions & DDIs With our innovative advanced models, researchers can accurately simulate drug drug interactions & assess their impact on renal function Understand more: buff.ly/3x7CRVQ #Newcells #Kidney #DrugDiscovery

Drug-induced #nephrotoxicity can be a major hurdle in new drug development Newcells solution: cutting-edge #kidney toxicity assays for in vitro renal drug safety/efficacy evaluation Learn how Newcells tailors projects to your needs: buff.ly/4aGE1p6 #DrugSafety

Fact File: Newcells retinal organoids Our eBook discusses iPSC-derived retinal #organoids & pigment epithelium for in vitro #diseasemodelling & preclinical drug testing. Discover these models & their applications. Download it here: buff.ly/3yrBUrI #Newcells #Retina

At Newcells, we build in vitro models to de-risk and improve #clinicaltranslation and #drugdiscovery. Find out more about our Lung Platform capabilities in this video featuring Dr Megan Webster 💡 #Newcells #DrugDiscovery #InVitro #Lung buff.ly/4brPE4C

Delighted to have Amy Mawdesley, Account Manager, representing Newcells at Innovation for Cell and Gene Therapies in Paris yesterday 🇫🇷 Discover our Retinal Pigment Epithelial (RPE) models here: buff.ly/44SlzZo #ICGT #CellTherapy #GeneTherapy #Retina

Colin Brown, Chief Innovation Officer, manning the booth at #TIDESUSA in Boston. Our team are looking forward to the final day! Stop by Booth #917 to say hi and chat to our experts 👋 #Newcells #InVitro #PredictiveData

Visual impairment caused by #AMD affects 1 in 3 people over the age of 75 years and more than 8 million people worldwide. iPSC technology offers the chance to investigate disease mechanisms and evaluate novel therapeutics. Download our e-book for more: buff.ly/3yrBUrI

Are you testing #therapeutic compounds in the #lung? 🫁 Using primary validated models can give you relevant throughput in a multicellular system, which closely reflects the in vivo environment. Discover more in the new lung eBook: buff.ly/4bz6Ogf #lungmodels #SAEC

Dr Colin Brown, Chief Innovation Officer, will be presenting on in vitro renal models at TIDES 2024 in Boston today: lnkd.in/eBYjtzN ⏰ 5:45 - 6:45 EDT Download the poster here: lnkd.in/eqg4cqEk #Newcells #Kidney #KidneyResearch #KidneyHealth #TIDESUSA

Discover how our retinal platform has become a robust #drugdiscovery asset to provide models and services globally. Dr Valeria Chichagova, Associate Director of iPSC Technology and Head of #Retina at Newcells can tell you more. Watch the video below ▶️ buff.ly/3yrq40K